Brivaracetam Approval Status and Dosing for Pediatric Partial-Onset Seizures
Brivaracetam is FDA-approved for the treatment of partial-onset seizures in children as young as 1 month of age, with a recommended starting dose of 2.0 mg/kg twice daily (maximum 100 mg twice daily for body weight >50 kg), and no titration is required. 1
Approval Status
Brivaracetam received FDA approval in 2016 for partial-onset seizures and has been approved for pediatric use down to 1 month of age 1. This represents a significant advancement, as the drug has demonstrated efficacy and safety across the pediatric age spectrum, from neonates through adolescents.
Dosing Regimen
Starting Dose
- Pediatric patients (1 month to <16 years): 2.0 mg/kg twice daily (administered as oral solution or tablets depending on age/ability to swallow)
- Maximum dose: 100 mg twice daily when body weight exceeds 50 kg 1, 2
Key Dosing Principles
No titration is required - this is a major practical advantage over many other antiepileptic drugs 1. The drug can be started at the target therapeutic dose immediately, which differs from medications like lamotrigine or topiramate that require slow titration.
Dose Adjustments
The dosing is weight-based and age-independent 2. Pharmacokinetic modeling has confirmed that 2.0 mg/kg twice daily achieves steady-state plasma concentrations in pediatric patients comparable to adults receiving 100 mg twice daily 2.
Important caveat: While the standard adult starting dose is 50 mg twice daily with potential adjustment to 25-100 mg twice daily based on tolerability 1, pediatric dosing follows the weight-based approach outlined above.
Special Considerations
Hepatic Impairment
Dose adjustment is recommended for all stages of hepatic impairment 1. This is critical to remember as it's one of the few situations requiring dose modification.
Renal Impairment
No dose adjustment needed for renal impairment - less than 10% is excreted unchanged in urine 1.
Drug Interactions Requiring Dose Consideration
- Rifampin co-administration: Consider increasing brivaracetam dose due to decreased concentrations 1
- Carbamazepine: Decreases brivaracetam exposure by 32%, though simulations suggest no routine dose adjustment needed 2
- Phenobarbital: Decreases exposure by 29%, though routine adjustment may not be necessary 2
- Valproate: Increases exposure by 11% 2
Levetiracetam Consideration
Critical pitfall: Brivaracetam showed no added therapeutic benefit when co-administered with levetiracetam 1. If a patient is already on levetiracetam, consider an overnight switch rather than adding brivaracetam, which can reduce behavioral adverse effects 3.
Efficacy Evidence
Clinical studies demonstrate:
- Response rates (≥50% seizure reduction): 25.8% at 3 months, with best responses in focal seizures 3
- Retention rates: 80.6% at 3 months, 66.7% at 6 months 3
- Efficacy confirmed in children as young as 1 month, with neonatal studies showing appropriate pharmacokinetics at 0.5 mg/kg twice daily 4
Safety Profile
The drug is generally well-tolerated in pediatric populations:
- Most common adverse effects: Somnolence (7.1%), decreased appetite (6.1%), irritability, and pyrexia 5
- 75.3% of patients report no adverse effects 3
- Only 14% required dose adjustment or discontinuation due to adverse effects 3
Administration Routes
Brivaracetam is available as:
- Oral tablets (10,25,50,75,100 mg)
- Oral solution (10 mg/mL) - preferred for younger children
- IV injection (50 mg/5 mL) - for when oral administration is temporarily not feasible, using the same dosing as oral regimen 1
The formulations are interchangeable without dose adjustment 1.